Europe Neoantigens Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Neoantigens Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Neoantigens Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Neoantigens Market Regional Analysis

6.2 Europe Neoantigens Market Revenue 2021-2028 (US$ Thousand)

6.3 Europe Neoantigens Market Forecast Analysis

7. Europe Neoantigens Market Analysis – by Treatment

7.1 Combination Therapy and Mono Therapy

7.1.1 Overview
7.1.2 Combination Therapy and Mono Therapy: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8. Europe Neoantigens Market Analysis – by Therapeutic Specialty

8.1 Gastrointestinal Cancer

8.1.1 Overview
8.1.2 Gastrointestinal Cancer: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.2 Lung Cancer

8.2.1 Overview
8.2.2 Lung Cancer: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.3 Solid Tumor

8.3.1 Overview
8.3.2 Solid Tumor: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.4 Urinary Systems Cancers

8.4.1 Overview
8.4.2 Urinary Systems Cancers: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.5 Melanoma

8.5.1 Overview
8.5.2 Melanoma: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.6 Head and Neck Cancer

8.6.1 Overview
8.6.2 Head and Neck Cancer: Europe Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

9. Europe Neoantigens Market – Europe Analysis

9.1 Overview

9.2 Europe

9.2.1 Europe Neoantigens Market Breakdown, by Key Country, 2024 and 2028 (%)
9.2.1.1 Europe Neoantigens Market – Revenue and Forecast Analysis – by Country
9.2.1.1 UK: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.1.1 UK: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.1.2 UK: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.2 Germany: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.2.1 Germany: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.2.2 Germany: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.3 France: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.3.1 France: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.3.2 France: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.4 Russia: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.4.1 Russia: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.4.2 Russia: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.5 Italy: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.5.1 Italy: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.5.2 Italy: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.6 Rest of Europe: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.6.1 Rest of Europe: Europe Neoantigens Market Breakdown, by Treatment
9.2.1.6.2 Rest of Europe: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. Company Profiles

12.1 Achilles Therapeutics plc

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Frame Cancer Therapeutics

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 Genocea

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Immunicum AB

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Medigene AG

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Moderna, Inc

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

Europe Neoantigens Market

Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)